Jyong Biotech Ltd. Ordinary Shares (MENS) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
MENS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MENS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export MENS earnings history in CSV or JSON format
Free sign-in required to download data
Jyong Biotech Ltd. Ordinary Shares (MENS) Earnings Overview
As of May 7, 2026, Jyong Biotech Ltd. Ordinary Shares (MENS) reported trailing twelve-month net income of -$3,019, reflecting +31.4% year-over-year growth. The company earned $-0.04 per diluted share over the past four quarters.
Looking at the long-term picture, MENS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2020.
Jyong Biotech Ltd. Ordinary Shares is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AEYE (-$3M net income, -7.6% margin), NUVB (-$146M net income, -325.3% margin), HALO ($317M net income, 22.7% margin), MENS has comparable earnings metrics. Compare MENS vs AEYE →
MENS Earnings vs Peers
Earnings metrics vs comparable public companies
MENS Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$3M | +31.4% | -$2M | $-0.04 | - | - |
| 2023 | -$4M | +33.6% | -$3M | $-0.06 | - | - |
| 2022 | -$7M | -57.9% | -$3M | $-0.09 | - | - |
| 2021 | -$4M | -119.1% | -$2M | $-0.06 | - | - |
| 2020 | -$2M | - | -$2M | $-0.03 | - | - |
See MENS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MENS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MENS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMENS — Frequently Asked Questions
Quick answers to the most common questions about buying MENS stock.
Is MENS growing earnings?
MENS EPS is $-0.04, with earnings growth accelerating to +31.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-3019.00.
What are MENS's profit margins?
Jyong Biotech Ltd. Ordinary Shares net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MENS's earnings?
MENS earnings data spans 2020-2024. The accelerating earnings trend is +31.4% YoY. Historical data enables comparison across business cycles.